These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6812750)

  • 21. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
    Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
    Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist.
    Igarashi M; Okuda T; Oh-i T; Koga M
    J Dermatol; 2000 Oct; 27(10):643-50. PubMed ID: 11092268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data.
    Arosio E; Montesi G; Zannoni M; Perbellini L; Paluani F; Lechi A
    Angiology; 1991 May; 42(5):408-13. PubMed ID: 2035893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
    Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
    Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
    Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
    Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.
    Wollersheim H; Thien T
    J Clin Pharmacol; 1988 Dec; 28(12):1089-93. PubMed ID: 3243924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.